Russell Abberley, Vice President and General Manager of Amgen UK and Ireland, has been confirmed as the ABPI President-Elect.
Russell Abberley confirmed officially appointed to lead the Association of British Pharmaceutical Industry through a major leadership shift.
On May 13, 2025 Russell Abberley will begin his two-year presidency after his current position as Amgen UK and Ireland Vice President and General Manager.
Since July 2020 Russell Abberley has served on the ABPI Board as an active member after more than 25 years of life sciences industrial experience.
Prior to his president role at ABPI he was the acting president after Susan Rienow assumed her position at Pfizer.
Abberley’s leadership phase occurs right before two essential plans from the NHS will be released: the NHS 10-Year Plan and the Life Sciences Sector Plan.
His leadership direction targets the UK to emerge as a top pharmaceutical research and development center to deliver advanced medical treatments that both patients and global investors will benefit from.
Abberley declared his dedication saying “I am proud about how well the UK has performed in life sciences leadership and innovation yet we need to do more to let UK patients get access to innovative medical treatments.”
As an industry supporter I am willing to join forces with government authorities toward achieving their goal to establish the UK as a global life sciences center.
The combined efforts of organizations will help improve national health as well as create vital economic expansion.
ABPI Chief Executive Richard Torbett endorsed the appointment by recognizing both the interim presidency work of Abberley and his established dedication towards industry growth and governmental partnerships.
During his presidency Abberley will advance UK life sciences objectives by driving innovation while securing global pharmaceutical leadership for Britain.
